Analyst firms · Citigroup · HAE
Citigroup HAE price target and rating history
Haemonetics Corporation (HAE) · Health Care
Citigroup rates Haemonetics Corporation (HAE) Buy with a $123 price target, as of its latest action on Sep 17, 2026. It has published 5 rating actions on HAE since December 2021, including 2 upgrades and 3 downgrades. Across 3 firms with a HAE price target in the last 12 months, the median target is $89. Citigroup's $123 is 38% above that.
- Current rating
- Buy
- Price target
- $123
- Median target, all firms
- $89
- Actions on HAE
- 5
Citigroup price target on HAE
Every Citigroup rating on HAE
- Sep 17, 2026
- Dec 11, 2025
- Jul 9, 2025
- Dec 15, 2021
- Dec 15, 2021
How other firms rate HAE
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Citigroup | Buy | $123 | Sep 17, 2026 |
| BofA Securities | Buy | $80 | May 22, 2026 |
| Barrington Research | Outperform | $89 | May 12, 2026 |
| Needham | Hold | Dec 15, 2025 |
Questions about Citigroup and HAE
- What is Citigroup's price target for HAE?
- Citigroup's latest stated price target for Haemonetics Corporation (HAE) is $123, from its action on Sep 17, 2026.
- What is Citigroup's rating on HAE?
- Citigroup rates HAE Buy, a bullish rating, as of Sep 17, 2026.
- When did Citigroup last change its view on HAE?
- On Sep 17, 2026, Citigroup upgrades to Buy from Neutral, price target $123.
- How does Citigroup's HAE target compare with other analysts?
- Across 3 firms with a HAE price target in the last 12 months, the median target is $89. Citigroup's $123 is 38% above that.
More HAE rating histories
All Citigroup ratingsHAE news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.